



Bleeding (hemorrhagic) disorders in children.


**Assistant of pediatric department
Tatyana Golovko**

The bleeding disorders is a group of diseases with increased bleeding, which is based on disorders in different parts of hemostasis.

Overview of Haemostasis



Blood coagulation *in vivo*



The three pathways that make up the classical blood coagulation pathway

Intrinsic

surface contact

XII → XII_a

XI → XI_a

IX → IX_a

X → X_a (VIII, PL, Ca⁺⁺)

prothrombin → thrombin (serine protease) (V, PL, Ca⁺⁺)


fibrinogen → fibrin → XIII_a → stable fibrin clot

XII – Hageman factor, a serine protease
 XI – Plasma thromboplastin, antecedent serine protease
 IX – Christmas factor, serine protease
 VII – Stable factor, serine protease
 XIII – Fibrin stabilising factor, a transglutaminase
 PL – Platelet membrane phospholipid
 Ca⁺⁺ – Calcium ions
 TF – Tissue Factor (_a =active form)

Extrinsic

TF:VII_a ← tissue damage

Common



This disorder may be due to:

1. A functional deficiency in the procoagulant mechanism. This may involve:
 - a. The platelets;
 - b. The procoagulant plasma component;
2. A functional excess in anticoagulant mechanisms.
 - c. Anticoagulant drugs;
 - d. Natural anticoagulants;
3. A functional excess in fibrinolytic mechanism.

Three types can be broadly identified:

“Coagulation-defect bleeds”

“Purpuric-type bleeds”

Mixed bleeds.

Differential diagnosis between coagulation disorders and purpuric disorders

Finding	Disorders of Coagulation	Disorders of Platelets or Vessels
Petechiae	Rare	Characteristic
Deep dissecting hematomas	Characteristic	Rare
Superficial ecchymoses	Common; usually large and solitary	Characteristic; usually small and multiple
Hemarthrosis	Characteristic	Rare
Delayed bleeding	Common	Rare
Bleeding from superficial cuts and scratches	Minimal Persistent	often profuse
Sex of patient	80-90% of inherited forms occur only in male patients	Relatively more common in females
Positive family history	Common	Rare (exc. vWF , hereditary hemorr. telangiectasia)

Table 118-1. Classification of Disorders of Hemostasis

Major Types	Disorders	Examples
Acquired	Thrombocytopenias	Autoimmune and alloimmune, drug-induced, hypersplenism, hypoplastic (primary, myelosuppressive therapy, myelophthisic marrow infiltration), disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome
	Liver diseases	Cirrhosis, acute hepatic failure, liver transplantation (see Chap. 129), thrombopoietin deficiency
	Renal failure	
	Vitamin K deficiency	Malabsorption syndrome, hemorrhagic disease of the newborn, prolonged antibiotic therapy, malnutrition, prolonged biliary obstruction
	Hematologic disorders	Acute leukemias (particularly promyelocytic), myelodysplasias, monoclonal gammopathies, essential thrombocythemia

Major Types	Disorders	Examples
Acquired	Acquired antibodies against coagulation factors	Neutralizing antibodies against factors V, VIII, and XIII, accelerated clearance of antibody-factor complexes, e.g., acquired von Willebrand disease, hypoprothrombinemia associated with antiphospholipid antibodies
	DIC	Acute (sepsis, malignancies, trauma, obstetric complications) and chronic (malignancies, giant hemangiomas, retained products of conception)
	Drugs	Antiplatelet agents, anticoagulants, antithrombins, and thrombolytic, hepatotoxic, and nephrotoxic agents
	Vascular	Nonpalpable purpura ("senile," solar, and factitious purpura), use of corticosteroids, vitamin C deficiency, child abuse, thromboembolic, purpura fulminans; palpable-purpura (Henoch-Schönlein, vasculitis, dysproteinemias; amyloidosis)

Table 118-1. Classification of Disorders of Hemostasis

Major Types	Disorders	Examples
Inherited	Deficiencies of coagulation factors	Hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), deficiencies of fibrinogen factors II, V, VII, X, XI, and XIII and von Willebrand disease
	Platelet disorders	Glanzmann thrombasthenia, Bernard-Soulier syndrome, platelet granule disorders
	Fibrinolytic disorders	α_2 -Antiplasmin deficiency, plasminogen activator inhibitor-1 deficiency
	Vascular	Hemorrhagic telangiectasias
	Connective tissue disorders	Ehlers-Danlos syndrome

Bleeding history

The bleeding history forms the basis of the laboratory tests and therapy. Asking patients if they are bleeders is not always helpful, as patients with mild to moderate bleeding abnormalities may not admit that their bleeding episodes are significant. Valuable information may be obtained if a patient has undergone major surgery; however, if this is not the case, inquiries as to minor surgical procedures, such as dental extractions and tonsillectomy, should be made. It is important to get information on the duration of bleeding, the type of bleeding and what procedure was necessary to stop the bleeding (blood transfusion?).

Physical Examination

Several clinical as well as laboratory features help differentiate clinical disorders associated with qualitative and quantitative platelet defects and abnormalities of the blood vessel wall (diseases of primary hemostasis) from those associated with disorders of the coagulation factors. Diseases of primary hemostasis have also been referred to as “purpuric syndromes.” Purpuric syndromes are characterized by capillary hemorrhages occurring chiefly in the skin and mucous membranes.

The usual lesions manifest spontaneous petechiae and ecchymoses, which result from a breakdown of the anatomic and physiological integrity of small vessel walls. Petechiae is pinpoint bleeding to small areas of skin. It can be measured less than 3 mm. Larger accumulations of skin lesions are usually called ecchymoses.



Gastrointestinal and genitourinary bleeding may occur spontaneously with abnormalities of platelets and/or coagulation factors. Deep hematomas, areas of palpable skin or soft tissue bleeding, and hemarthroses are most often associated with coagulation factor deficiencies or abnormalities. It is important to note that antecedent trauma or surgery, such as tooth extraction, tonsillectomy, or circumcision can be referred to excessive bleeding. Recurrent bleeding for several days usually indicates as an underlying bleeding disorder. In women, a careful history of their menstrual bleeding pattern gives valuable information about the nature of their hemostatic mechanism.

LABORATORY EVALUATION OF HEMOSTATIC DISORDERS

Understanding of the physiology of primary and secondary hemostasis is important for the interpretation of diagnostic laboratory tests and for the subsequent management of patients with hemostatic disorders. The type of bleeding may be of significant help in designing the program of hemostatic laboratory tests. This is accomplished by performing a platelet count, a bleeding time, an activated partial thromboplastin time (aPTT) and a prothrombin time (PT), and a thorough review of the patient's peripheral blood smear.

The platelet count

is performed to detect thrombocytopenia, which is defined as a platelet count of less than $150,000/\mu\text{L}$. The test can be considered as reliable down to a platelet count of $30,000/\mu\text{L}$. The finding of an unexpected thrombocytopenia should be confirmed by a review of the peripheral blood smear. The possibility of the existence of red blood cell fragments or of a pseudothrombocytopenia may provide clues for further evaluation of the patient.

The bleeding time

is defined as the time between the infliction of a small standard cut and the moment the bleeding stops.

Bleeding time measures the interactions of the platelets with the vessel wall and the subsequent formation of the primary hemostatic plug. A long bleeding time will be recorded either when the number of platelets is decreased, their function is abnormal, or there is defect of the vessel wall. The bleeding time may also be prolonged when there is a decrease of plasmatic factors, especially the VWF (von Willebrand factor) or fibrinogen.

The various methods for performing the bleeding time are basically modifications of two techniques:

the bleeding time according to Duke;

the bleeding time according to Mielke.

The *prothrombin time (PT)*

The prothrombin time may be prolonged because of a deficiency of a factor(s) of the extrinsic coagulation pathway, i.e, factors II, V, VII, X, and/or fibrinogen. A circulating anticoagulant directed against one or more of these factors may also cause a prolongation of the PT.

The *aPTT* (activated partial thromboplastin time)

In the old “cascade” theory of coagulation, the aPTT involves factors of both the intrinsic and common pathway. The aPTT may be prolonged as a result of a deficiency of one or more of these factors or of the presence of inhibitors that affect the functions of the factor(s). A decrease in factor levels to less than 30% of normal are usually required to prolong the aPTT. The aPTT will not detect deficiencies of factors VII and XIII, the factor that crosslinks fibrin.

The thrombin time (TT)

as part of the screening procedures. The thrombin time will be prolonged when the levels of plasma fibrinogen are very low, and when fibrinolytic split products, abnormal fibrinogen (dysfibrinogenemia), and/or heparin are present.

Interpretation of the Screening Tests of Hemostasis

Discrimination of the majority of the inherited and acquired hemostatic disorders is possible by looking at the results of the three screening tests: aPTT, PT, and TT.

- Patients with a prolonged aPTT and normal PT have abnormal activities of factors in the first stage (intrinsic) of the coagulation mechanism (i.e., factors VIII, IX, XI, and XII). Deficiencies of prekallikrein and HMW kininogen are possible. Whereas deficiencies of factor XII, prekallikrein, and HMW kininogen (high-molecular-weight kininogen, XV factor, Williams factor) are not associated with bleeding, deficiencies of factors VIII, IX, and XI will cause bleeding.

- ❑ A prolonged PT and a normal aPTT and TT may indicate a factor VII deficiency. Inherited or acquired deficiencies of factors II, V, VII, and X have to be considered if a prolonged PT and aPTT and a normal thrombin time are found.
- ❑ A prolongation of aPTT, PT, and thrombin time may reflect fibrinogen deficiency or dysfibrinogenemia.



- ❑ Most congenital deficiencies are single, whereas acquired abnormalities caused by vitamin K deficiency, liver disease, disseminated intravascular coagulation (DIC), or anticoagulant therapy which causes multiple coagulation defects.
- ❑ A prolonged bleeding time in the presence of a normal platelet amount is usually a sign of an abnormality of platelet–blood vessel interaction (e.g., von Willebrand disease).

PLATELET DISORDERS

Though platelets are classified as cells, they are actually cytoplasmatic fragments derived from megakaryocytes in the bone marrow. Platelet formation and release probably occur through the sinus endothelial cells. Platelets remain in the circulation for approximately 8–10 days. The normal platelet amount ranges from 150,000/ μL to 400,000/ μL .

The diameter of normal platelets is 1–4 μm . At a given point, 70% of the platelets are in the circulation and 30% are in the spleen (splenic pool).

The daily platelet production is 40,000/ μL and can be increased eightfold.

Thrombocytopenia

thrombocytopenia occurs when the platelet amount drops below $150,000/\mu\text{L}$. The bleeding usually occurs when the platelet amount is less than $100,000/\mu\text{L}$.

Spontaneous bleeding usually occurs with platelet amount less than $20,000/\mu\text{L}$.

Thrombocytopenia is due to either decreased bone marrow production of platelets or increased destruction and sequestration of the platelets from the circulation, or both.

Classification of Thrombocytopenia

Decreased platelet production

- Marrow failure (e.g., aplastic anemia)
- Marrow infiltration (e.g., leukemia, MDS)
- Marrow depression—cytotoxic drugs, radiation
- Selective megakaryocyte depression—drugs, ethanol, viruses, chemicals
- Nutritional deficiency—megaloblastic anemia
- Hereditary causes (rare)—Fanconi syndrome, amegakaryocytic hypoplasia, absent radii syndrome, Wiskott-Aldrich syndrome

Increased platelet destruction

Immune

- Idiopathic thrombocytopenic purpura
- Other autoimmune states—SLE, CLL, lymphoma
- Drug-induced: heparin, quinidine, quinine, gold, penicilline, cimetidine
- Infectious—HIV, other viruses, malaria
- Posttransfusion purpura
- Neonatal purpura

Nonimmune

- DIC**
- Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome**
- Cavernous hemangioma**
- Cardiopulmonary bypass**
- Hypersplenism**

MDS, myelodysplastic syndrome; SLE, systemic lupus erythematosus; CLL, chronic lymphocytic leukemia; DIC, disseminated intravascular coagulation.

Thrombocytopenia Due to Decreased Platelet Production

Thrombocytopenia due to decreased platelet production means that the bone marrow is unable to keep up with normal platelet requirements.

Thrombocytopenia frequently occurs in patients with underlying malignancies who had received chemotherapy or radiotherapy that destroyed the hematological stem cells. These patients require supportive therapy including platelet transfusions if they are bleeding.

✓ Megaloblastic anemia, including vitamin B_{12} and folic acid deficiencies, can present as isolated thrombocytopenia, although usually, all cell lines are affected.

The hereditary causes of thrombocytopenia are quite rare. In amegakaryocytic thrombocytopenia, the platelets are normal or small in size, the platelet life span is normal or only slightly reduced, and the bone marrow biopsy shows a marked reduction in the number of megakaryocytes.

Thrombocytopenia Due to Increased Platelet Destruction

Isolated thrombocytopenia is caused by increased platelet destruction. In these patients, the rate of platelet destruction cannot be compensated by the bone marrow with increased platelet production. These patients have isolated thrombocytopenia, and the number of megakaryocytes in the bone marrow is normal or increased. The platelet life span is shortened.

Immune Thrombocytopenia

Immune thrombocytopenia is an increase of platelet destruction caused by immunological mechanisms. The sensitization of platelets by immunoglobulin G (IgG) and IgM antibodies reacting with antigenic sites (usually glycoprotein [GP]IIb/IIIa in idiopathic thrombocytopenic purpura [ITP], platelet alloantigens in post-transfusion purpura, and neonatal isoimmune purpura) on the platelet membrane is the main cause of platelet destruction.


Idiopathic Thrombocytopenic Purpura

Acute ITP in children is equally common in boys and girls, has its peak incidence at age 2 - 4 yr, and frequently follows a viral infection or vaccination.

More than 80% of these children have a spontaneous remission of their illness in 2 - 4 wk. Serious morbidity or mortality is rare (approximately 1%), but the recovery of the platelets can be forced by the administration of high doses of intravenous IgG.

Incidence Children: 5 per 100,000.

Estimated Prevalence of Secondary ITP in the US



Causes

The exact causes of ITP are yet unknown, but there is currently research going on to try and determine what causes this disease.

There are many theories, most state that ITP is a multifactorial disease with a strong genetic predisposition.

Researchers are currently looking for multiple instances of ITP in a family, and have found that in some cases ITP can be passed from mother to child.

Theories

Three most common theories for ITP are:

- The Microbial Trigger Theory
- The Molecular Mimicry Theory
- The Free Radical Damage Theory

The Microbial Trigger Theory

- Related to the destruction of platelets to a chemical called interleukin 12 that is released when the body is fighting a bacterial infection.
- They believe that in some people this interleukin 12 can inadvertently activate dormant self reactive cells which damage is the releaser of an autoimmune process.
- If that cell is a specialized platelet then it would develop ITP.

The Molecular Mimicry Theory

- This theory says that someone can develop ITP when the bodies T-helper cells recognize a viral or bacteria amino-acid sequence that can be determinant on the surface of a platelet.
- Normally T-helpers are inhibited by other immune agents.
- If there is a dysfunction in the production of these inhibiting agents then the self reactive T-helper cells are free to target destruction platelets.


Free Radical Damage Theory

- DNA is damaged by “free radicals”.
- Free radicals are compounds that build up in the body, which need electrons in order to become stable.
- If they steal these electrons from DNA they can cause mutations which could effect the immunes system, and possibly trigger ITP or other autoimmune diseases.

Pathophysiology

ITP is caused by an autoantibody - in generally IgG - that binds to specific platelet glycoproteins, especially GP IIb, IIIa. These antibodies attached to the platelet membranes may bind complement and cause accelerated platelet destruction through phagocytosis by the reticuloendothelial cells in the spleen and the liver. A compensatory increase in bone-marrow megakaryopoiesis usually occurs, which may initially prevent or delay the development of more severe thrombocytopenia. In a few cases, the measurement of the platelet life-span may be helpful. On rare occasions, platelets of patients with apparent ITP have a nearly normal life-span. The cause of the thrombocytopenia in these patients is unclear, an early myelodysplastic syndrome should be ruled out.

Two Processes Involved in Immune Thrombocytopenic Purpura



Classification of ITP

- Primary ITP:
 - Idiopathic - etiology is unknown;
 - No clinically evident secondary form.

- Secondary ITP:
 - Associated with infections, immunizations/vaccines

Classification of ITP

Secondary ITP

- Antiphospholipid syndrome;
- Autoimmune thrombocytopenia (e.g., Evans syndrome);
- Common variable immune deficiency;
- Infection with cytomegalovirus, *Helicobacter pylori*, hepatitis C (HCV), human immunodeficiency virus (HIV), varicella zoster;
- Lymphoproliferative disorders;
- Side effect of bone marrow transplantation;
- Side effect of vaccination (i.e. MMR);
- Systemic lupus erythematosus.

Classification of ITP:

Disease phases

- Newly diagnosed (acute) ITP:
 - Less than 6 months;
- Chronic ITP:
 - More than 6-12 months;
- Refractory ITP:
 - Treatment failure by splenectomy.

Symptoms of ITP

- Excessive bleeding after minor injuries;
- Spontaneous bleeding from the mouth and nose;
- Unexplainable or spontaneous bruising;
- Excessive internal bleeding;
- Disturbed sleep cycle/
Insomnia;
- Irregular appetite;
- Depression.



Depression and ITP

ITP is accompanied by short term or more permanent depression.

This is because 2% of the body's serotonin is stored in the platelets; when the platelets are destroyed neurotransmitters rise the mood.

Platelets also carry Serotonin's "parents" chemicals called L-Tryptophan. This L-Tryptophan is able to pass through the blood brain barrier, so it's loss is the probable cause of the sleep/ eating irregularities.

Diagnosis of ITP

- Platelet count:
 - Less than $100 \times 10^9/L$ (rather than $150 \times 10^9/L$)
- Medical History;
- **Response to therapy;**
- Peripheral Smear;
- Physical Exam;
- Bone marrow aspiration and biopsy:
 - Not routinely done;
- Antiplatelet Antibody Testing.

Indications for Treatment

American Society of Hematology (ASH) suggests:

- Platelet amount $> 30 \times 10^9/L$ usually have few or no symptoms and require no treatment;
 - Avoid treatment in patients with mild, asymptomatic disease
- Platelet amount $< 30 \times 10^9/L$ have treatment recommendations based on the presence and severity of associated bleeding symptoms;
- Hospitalization and emergent treatment is indicated if:
 - Severe bleeding occurs, regardless of platelet amount;
 - Platelet amount $< 20 \times 10^9/L$ and signs/symptoms of mucocutaneous bleeding is present.

Goals of Treatment

- Obtain a hemostatic platelet amount to prevent bleeding:
 - Individualized to the patient;
- Minimizing toxicity associated with treatment;
- Achieve the long-term remission.

ITP Treatment Options

- **1st line:**
 - Corticosteroids;
 - Intravenous immunoglobulins (IVIg);
- **2nd Line:**
 - Splenectomy;
 - Thrombopoietin Receptor Agonists (in adults);
 - Rituximab (in adults);
- **3rd Line:**
 - Other immunosuppressive agents.

ITP Treatment Options: Corticosteroids

- **Prednisolone:**
 - Mechanism of Action:
 - Impair clearance of platelets in the bone marrow and peripherally
 - Reduce antibody production
 - Dose:
 - 1 – 2 mg/kg/day PO as single or divided doses
 - Usually responds within 2 - 3 weeks
 - Response rate: 50 – 75%
 - Taper within 4 – 6 weeks following platelet response
 - Side effects: numerous

ITP Treatment Options:

IVIg

- **IVIg:**

- Mechanism of action:

- Undefined and potentially multifactorial

- Dose:

- Variable regimen

Dose: 0.4 g/kg/d x 5 days (alternative: 1 g/kg/d x 2 days)

- Side effects:

- hypersensitivity
- headache
- renal failure
- nausea/vomiting
- alloimmune hemolysis
- pulmonary edema

ITP Treatment Options: Splenectomy

- **Splenectomy:**

- Mechanism of action:

- Removes a primary site of platelet destruction and increases platelet amount
- Possible site of autoantibody production

- Side effects: increased risk of infection, thrombosis, pulmonary hypertension

- Vaccination recommended:

- haemophilus influenzae B, pneumococcal and meningococcal

EMERGENCY TREATMENT OF ITP

Platelet transfusion + high dose steroids

Platelet transfusion + continuous IVIG

Antifibrinolytics

Emergent splenectomy

Neonatal Purpura

Neonatal thrombocytopenia may develop due to isoimmunization of the mother against fetal platelets with subsequent transplacental transfer.

The incidence of alloimmune neonatal purpura is 1 in 5000 deliveries. The most commonly involved antigen is PIA1, an antigen that is present on platelets in 98% of the population.

The infant shows generalized purpura at delivery, and platelet amount are usually below 30,000/ μ L. Intracranial hemorrhage is a severe complication that occurs in about 10% of affected infants.

INHERITED DISORDERS OF COAGULATION

There is a large number of inherited disorders of coagulation; however, only three are relatively common:

- I. Von Willebrand's Disease (vWD),**
- II. Factor VIII deficiency (hemophilia A),**
- II. Factor IX deficiency (hemophilia B; Christmas disease).**

All of the others are rare.

von Willebrand's Disease (vWD)

von Willebrand disease is the most common inherited disorder of primary hemostasis.

The prevalence of vWD mutations may be as high as 1 to 2% of the population, although most of cases are never diagnosed; the prevalence of *clinically evident* vWD is much lower.

The clinical and laboratory manifestations of vWD are extremely heterogeneous, and diagnosis can sometimes be difficult.

Three main subtypes of vWD have been defined:

Type 1: the most common ($\geq 70\%$ of cases of clinical vWD). There is a decrease in the concentration of vWF in the plasma (i.e., a **quantitative defect**), but all sizes of multimers, including the very high-molecular-weight multimers, are present.

The **inheritance pattern is autosomal dominant.**

Type 2: In Type 2 vWD, there is a **qualitative defect** in vWF. Several different subtypes of vWD Type 2 are described. Inheritance is autosomal dominant in most cases, although a few types display autosomal recessive inheritance.

Type 2A: In Type 2A, there is a deficiency of the high-molecular-weight multimers of vWF, but the absolute level of total vWF is normal. This is the most common variant of vWD Type 2.

Type 2B: In Type 2B, the vWF appears with an abnormally increased affinity for the vWF receptor (GP Ib-IX/V) on the platelet surface. Too much vWF is tied up on the platelet surface, rather than being in the plasma, and is therefore not able to bind to subendothelial collagen. The diagnosis of Type 2B vWD is made by demonstrating *increased* platelet agglutination with ristocetin rather than decreased ristocetin agglutination, as seen in the other types of vWD. Mild thrombocytopenia is common.

Type 2M: In Type 2M vWD, there is a mutation that affects some important functional domains of the protein (think “**M**” for **M**utation). A variety of mutations in different regions of the protein have been described.

Type 3: In Type 3 vWD, there is a **total or near-total absence of vWF** in the plasma. Type 3 vWD is rare. The patients have markedly decreased factor VIII level and thus they may have bleeding manifestations resembling hemophilia. The inheritance pattern is autosomal recessive; some cases appear to represent homozygous Type 1 vWD.

Clinical Manifestations of von Willebrand's Disease

Most cases of vWD present with the typical picture of a **primary hemostatic defect**: mucocutaneous bleeding (epistaxis, bleeding gums), easy bruising, and immediate bleeding from cuts, incisions, and dental extractions. Most patients have a mild to moderate bleeding tendency. *The severity of illness in different patients is highly variable, and it can also vary over time in individual patients.* The clinical phenotype can vary between different members of the same family.

The laboratory manifestations of vWD can also be highly variable; sometimes laboratory tests must be repeated several times to make a firm diagnosis. As noted, **the inheritance pattern of most cases of vWD is *autosomal dominant*.**

Type 3 vWD presents with a mixed picture. Since the factor VIII levels are low, the patients may have hemarthroses, muscle hematomas, and other manifestations of defects of secondary hemostasis in addition to mucocutaneous bleeding.

Laboratory Diagnosis of von Willebrand's Disease

The most important diagnostic tests for vWD are the *bleeding time*, *ristocetin cofactor assay*, a *quantitative assay of vWF concentration* (ELISA or Laurell rocket immunoelectrophoresis), *ristocetin-induced platelet aggregation*, and *agarose gel electrophoresis* to determine whether the high-molecular-weight multimers are present or absent.

In vWD Type 1, the BT will usually be prolonged. The PTT may also be slightly prolonged due to decreased factor VIII concentration. The absolute level of vWF is decreased; the vWF multimer pattern is normal (the highmolecular-weight multimers are present, but the concentration of all sizes of multimers is decreased). Platelet aggregation with ristocetin and the ristocetin cofactor activity are decreased; platelet aggregation with other agents is usually normal.

Type 2A is diagnosed by demonstrating an absence of the high-molecular-weight multimers by agarose gel electrophoresis. The absolute concentration of vWF is usually normal.

Type 2B is diagnosed by demonstrating *increased* platelet agglutination with ristocetin. Plasma from patients with Type 2B shows a decrease in vWF; agarose gel electrophoresis demonstrates a decrease in high-molecular-weight multimers (because they are all stuck on the platelets). Mild thrombocytopenia is common.

Diagnosis of **Type 2M** requires sophisticated techniques, which are not widely available; therefore, specimens must usually be sent to reference laboratories that specialize in coagulation.

Type 3 is diagnosed by demonstrating a total or near-total absence of vWF in the plasma.

Treatment of von Willebrand's Disease

Most cases of vWD Type 1 can be very successfully treated with *desmopressin acetate* (**DDAVP**), which causes release of preformed vWD from endothelial cells. Desmopressin acetate is cheap, is safe, and has no infectious risk. It can be administered either intravenously or intranasally (0.3 mcg/kg IV, or 150 mcg per nostril). Other types of vWD, or a patient with Type 1 requiring major surgery and may need replacement therapy. There are no commercially available vWF concentrate preparations, but some factor VIII concentrate preparations contain enough vWF to be effective. **Factor VIII concentrates have therefore replaced cryoprecipitate as the treatment of choice for vWD requiring factor replacement.**

Table 2. Indications for desmopressin in different types of von Willebrand disease

Type	Response
1	Usually effective
2A	Usually ineffective
2B	May be contraindicated
2M	Predicted to be ineffective
2N	Rarely effective
3	Ineffective

Indications for clotting factor concentrate administration in vWD

- Type 2 or 3 vWD:
 - Active bleeding;
 - Surgery or other invasive procedure.
- Type 1 vWD with inadequate response to DDAVP.

TREATMENT OF VON WILLEBRAND DISEASE WITH HUMATE-P[®]

Classification of VWD	Indication for treatment	Dosage (<u>ristocetin cofactor units/kg</u>)
Mild type I (VWF >30%)	Major bleeding or major invasive procedure/surgery	1. Load with 40-60 U/kg 2. 40-50 U/kg every 8-12 h (keep VIII >50%) 3. 40-50 U/kg/day for up to 7 days
Moderate type I (VWF < 30%)	Minor bleeding, or minor invasive procedure	40-50 U/kg x 1-2 doses
Moderate or severe type I	Major bleeding or surgery	1. Load with 50-75 U/kg 2. 40-60 U/kg every 8-12 h for 3 days (keep VIII >50%) 3. 40-60 U/kg/day for up to 7 days
Type II or III	Minor bleeding, or minor invasive procedure	40-50 U/kg x 1-2 doses
Type II or III	Major bleeding or major invasive procedure/surgery	1. Load with 60-80 U/kg 2. 40-60 U/kg every 8-12h for 3 days (keep VIII >50%) 3. 40-60 U/kg/day for up to 7 days

(Based on manufacturer's guidelines; see also [Mannuci PM, Blood 2001;97:1915](#))

The Hemophilias

The hemophilias are *inherited disorders of the coagulation cascade*. Deficiency of **factor VIII (hemophilia A)** is the most common (~85% of cases). **Factor IX deficiency (hemophilia B)** is second (~15%), and all others are rare.

The incidence of hemophilia A is estimated at 1 per 5,000 to 10,000 male births in the United States; the incidence of hemophilia B is approximately 1 in 30,000 male births.

Hemophilia A and B are both inherited as **X-linked recessive**: women are carriers, men develop the disease. All of the other factor deficiencies are inherited as autosomal recessive.

Factor XI deficiency (sometimes called **hemophilia C**) is the third most common inherited disorder of coagulation factors but is much less common than deficiency of factors VIII or IX.

Clinical Features

The clinical features of hemophilia A and B are identical. The manifestations are those of deficiencies of secondary hemostasis: **hemarthroses, muscle hematomas, soft tissue bleeding, and delayed but prolonged bleeding from cuts or incisions.** Recurrent hemarthroses result in joint destruction and can be disabling. Bleeding into muscle or soft tissue can result in a compartment syndrome, with compression of nerves and blood vessels; this may require fasciotomy for relief.



Muscle hematoma (pseudotumor)



Hemarthrosis (joint bleeding)

LONG-TERM COMPLICATIONS OF HEMOPHILIA



Joint destruction

Nerve damage

Hemophilic arthropathy





Fig 3. Arthroscopic view of the inflamed synovium in a patient with haemophilia. Note that the villi are large and haemosiderin-laden. Reproduced with permission from Lippincott Williams & Wilkins (Dunn *et al*, 2004).



“Target joint” = irreversibly damaged joint with vicious cycle of injury and repeated bleeding

Intracranial bleeding is an especially serious complication, and even minor head trauma in a severe hemophiliac should be treated with factor replacement. *There is no such thing as minor head trauma in a severe hemophiliac.* Another potentially lethal complication is bleeding into the soft tissues of the oropharynx; dissection of the hematoma into the trachea can result in airway occlusion and asphyxia.

Children with severe hemophilia usually begin to have problems at about 9 to 12 months of age, at about the time they begin to walk. Some will come to medical attention earlier due to prolonged bleeding after circumcision or other surgery. Mild or moderate cases may not have problems until they undergo a severe challenge to hemostasis, such as a dental extraction, major surgery, or severe injury.

Most patients will have a family history of pathologic bleeding on the maternal side, including maternal brothers, uncles, and other male relatives. A history of bleeding on the paternal side, or a history of bleeding in female relatives, suggests vWD or another clotting factor deficiency.

The severity of bleeding depends on the level of the deficient factor. Approximately half of hemophilia A cases have severe disease, with a total absence of detectable factor activity.

Hemophilia: Factor Level versus Severity*

Severity	Factor Level	Manifestations
Severe:	<1%	Spontaneous bleeding; bleeding with minor surgery or trauma
Moderate:	1–5%	Spontaneous bleeding uncommon; may bleed with surgery or trauma
Mild:	5–20%	No spontaneous bleeding; may bleed with major trauma or surgery

*Generally applies to both factor VIII and factor IX deficiencies; may not apply to deficiency of other factors.

Laboratory Diagnosis

The PTT is prolonged; the PT is normal. Mixing studies show correction of the PTT with normal plasma. Specific diagnosis and distinction of factor VIII deficiency from factor IX deficiency require assay of the factor levels and demonstration of a deficiency. **It is critical to distinguish factor VIII deficiency from factor IX deficiency because the treatment is completely different.** Remember, it is impossible to distinguish hemophilia A from hemophilia B based on clinical or family history. Clotting factor assays also allow you to predict clinical severity if it is not obvious from the history.

Treatment

Treatment depends on which factor is deficient, the severity of the deficiency, and the nature of the bleeding, injury, or planned surgery. Various highly purified preparations of factors VIII and IX are available. These have been intensively treated to prevent infection, and are generally very safe. Recombinant forms of both are also available.

Always be sure to determine which factor the patient is deficient in before you start replacement therapy. For severe bleeding or major surgery, it is desirable to achieve peak factor levels of 100% and maintain minimum levels $>50\%$. For minor bleeding or surgery, aim for peak levels of $\sim 50\%$ and minimum levels $\geq 25\%$. A variety of different formulas are available for dosing factor concentrates.

Dosing clotting factor concentrate

- 1 U/kg of factor VIII should increase plasma level by about 2% (vs 1% for factor IX).
- Half-life of factor VIII 8-12 hours, factor IX 18-24 hours.
- Volume of distribution of factor IX about twice as high as for factor VIII.
- Steady state dosing about the same for both factors – initial dose of factor IX should be higher.




Fig 1. Pharmacokinetics of factor VIII infusion. The goal is to attain 100% factor VIII levels in a theoretical 70-kg man. The plasma volume is 3,500 mL (70 kg \times 50 mL/kg). Infusion of 3,500 U of factor VIII will increase the factor VIII level from 0% to 100%. With a half-life of 12 hours, factor VIII will decrease to 50% at 12 hours. Infusion of 1,750 U of factor VIII at 12 hours will increase the factor VIII level from 50% to 100%; infusion of 1,750 U of factor VIII at 24 hours will increase the factor VIII level from 50% to 100%, and so on.

Factor replacement in severe hemophilia A

Site of bleed	Desired factor level	Dose	Other
Joint	40-50%	20-40 U/kg/day	Rest, immobilization.
Muscle	40-50%	20-40 U/kg/day	Risk of compartment syndrome or neuro compromise
Oral mucosa	50% initially	25 U/kg *1	Follow with antifibrinolytic therapy
Epistaxis	Initially 80-100%, then 30% unit healed	40-50 U/kg then 30-40 U/kg daily	Pressure, packing, cautery
GI disorders	Initially 100%, then 30% unit healed	40-50 U/kg then 30-40 U/kg daily	Endoscopy to find lesion
GU disorders	Initially 100%, then 30% unit healed	40-50 U/kg then 30-40 U/kg daily	Rule out stones, UTI
CNS	Initially 100%, then 50% unit healed	50 U/kg then 25 U/kg q 12 h infusion	Test for inhibitor before sugery
Trauma or sugery	Initially 100%, then 50% unit healed	50 U/kg then 25 U/kg q 12 h infusion	

- Give factor q 12 hours for 2-3 days after major surgery, continue with daily infusions for 7-10 days
- Trough factor levels with q 12 h dosing after major surgery should be at least 50-75%
- Most joint and muscle bleeds can be treated with “minor” (50%) doses for 1-3 days without monitoring

Liver disease in hemophilia

- Hepatitis C is still a problem, though incidence is falling with safer factor concentrates
- Treatment for hepatitis C with interferon often causes thrombocytopenia
- Liver transplantation is made occasionally (cures hemophilia)
- All newly diagnosed hemophiliacs should be vaccinated against hepatitis A and B

ACQUIRED FACTOR VIII DEFICIENCY

- Due to antibody to factor VIII (most common autoimmune factor deficiency)
- Most patients elderly
- Often presents with severe soft tissue or mucosal bleeding (different bleeding pattern than inherited hemophilia)
- Laboratory: prolonged aPTT not corrected by mixing, very low factor VIII activity
 - Normal thrombin time and platelet amount
- Treatment: rVlla, FEIBA, immunosuppression



BEST WISHES!!!